Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — Non-Deal Roadshow (June 2025)
14 slides from Clinuvel Pharmaceuticals's roadshow presentation, Jun 24, 2025
Slide 1: A Story of Innovation & Longevity, Resistance & Resilience
CLINUVEL A STORY OF INNOVATION & LONGEVITY, RESISTANCE & RESILIENCE 23-24 June 2025 Frankfurt, Diisseldorf Philippe Wolgen, Managing Director ASX: CUV Borse Frankfurt: UR9 ADR Level I: CLVLY
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT cuyever croup This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown ri resulls, performance, or achievements to differ expressed or implied by such
Slide 3: Evaluation
EVALUATION 20 years going concern, 39 unremarkable financial audits “a team pursuing an illusion which our “a company wilh no hope” “an attempt in vain own teams would never devole Lime on” 2005 Goldman Sachs (AUS) of putting funds to a molecule 2006 CEO large pharma that will never come to “Vitilig
Slide 4: Focus on Melanocortin Innovation
FOCUS ON MELANOCORTIN INNOVATION a concentric strategy diversifying & mitigating risks — peptides + delivery technologies afamelanotide EPP, vitiligo 3 ACTH -— generic relapsing MS, infantile spasms WHERE IS CLINUVEL ON THIS TRAJECTORY? SCENESSE® commercial in EPP. in trials in vitiligo small molecu
Slide 5: Biopharmaceutical Cases
BIO. PHARMACEUTICAL CAS) Great companies which faced adversity.. Opthea — suspended Suspended - March 2025 MCAP: from ASL.4b to zero Lead program failed in Phase III trial, in restructuring Mesoblast — AS$2.1b 2 failed FDA submissions. succeeded at 3rd attempt in 20235, debt USSII9m AS99m Imugene De
Slide 6: Biopharmaceutical Cases: What's the upshot?
BIO- PHARMACEUTICAL CASES What's the upshot? * adversities: technological failure, lack of funding ¢ US deepest capital market for biotechnology ¢ Nasdaq *70 trading below cash levels, 3 ASX life sciences trading below cash ¢ 4 melanocortin companies left: CUV, RYTM, ANIP, LG Chem * cash is key to e
Slide 7: Finance
FINANCE Anticipation of downceycles & capital needs Strong Earnings Performance debt free 40.0 0.80 cost of equity 5.3% 35.0 0.70 OPEX, 2005-2014 — ASI29.5m 30.0 0.60 OPEX, 2015-2024 A8222.1m ” a 20.0 040 CAGR 5.0 0.30 revenues 38.0% expenses 20.0% 10.0 0.20 profit 25.7% 50 q anh cash reserves 2 ASI
Slide 8: CLINUVEL's Future
CLINUVEL’S FUTURE What are the investments leading to? to SCENESSE® expansion in EPP SCENESSE® in vitiligo NEURACTHEL® (ACTH) to enter US generic market Expansion to next gen formulations Integrate manufacturing in house . Complementary technologies to be acquired/in licensed Expanded with PhotoCosm
Slide 9: A Paradox
A PARADOX NPAT CAGR 25% (7yrs) versus share price decline NPAT (ASm) and share price (ASX:CUV, AS) h \ \ pw a fi f te) 2017 2018 2019 2020 —Close —=NPAT 2021 2022 2024
Slide 10: Catalysts & Calendar I
CATALYSTS & CALENDAR I 2025 — 2026 Commercial Financial year end results FY25 4th week August srowth : = Soonitene EMA decision dosage expansion adults QO4 2025 EMA re file adolescents SCENESSE® Q4 2025 Health Canada decision marketing authorisation: sans SCENESSE® in EPP 04 2025 Distribution expans
Slide 11: Catalysts & Calendar II
CATALYSTS & CALENDAR II 2025 — 2026 Clinical, CUVI05 vitiligo — primary protocol complete HI 2026 regulatory CUVIO5 Tirst results H2 2026 Start CUV053, variegate porphyria study HI 2026 Communications, Non deal roadshows DE. USA, AUS Hl/2 2025 IR, PR Premarketing activities PhotoCosmetics Q3/4 2025
Slide 12: Summary
SUMMARY 2005 — 2026 I. tv 3. 4. From high-risk novel technology to profitability Expertise retained, & expanded Cash reserves of =AS200 million to execute i. expanded access SCENESSE® - Europe, USA, RoW ii new product development — pharmaceutical & PhotoCosmetic iii. vertical integration iv. M&A Nea
Slide 13: Shareholder Address
Shareholder address Globally scanning publicly listed biotechnology companies there are very few peer comparisons to CLINUVEL. Against all odds our team has achieved commercial success once, and there is no doubt we will prolong its economic performance. The firm's cash reserve has served shareholde
Slide 14: Thank You for Your Interest
CLINUVEL THANK YOU FOR YOUR INTEREST Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD Head of Investor Relations: Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD : https: www.clinuvel.com/investors/contact-us Investor Enquiri Level 22, 535 Bourke Street, Melbourne —
Clinuvel Pharmaceuticals — Non-Deal Roadshow (June 2025) on 6ix